摘要
目的观察替考拉宁治疗并发肠球菌属感染的重症胰腺炎（SAP）患者临床价值。方法回顾性分析2005年9月-2008年12月湖南省人民医院肝胆科收治的并发肠球菌属感染SAP患者42例的临床经过，观察其临床、细菌学疗效以及不良反应发生率。结果替考拉宁治疗并发肠球菌属感染的SAP临床有效率为80．9％，细菌清除率为85．7％，未见明显不良反应发生。结论替考拉宁治疗并发肠球菌属感染的SAP疗效显著，安全性好，使用经济方便，值得在临床上推广应用。
OBJECTIVE To observe the clinical value of the teicoplanin in the treatment of severe acute pancreatitis （SAP） patients with Enterococcus infection. METHODS The clinical course of 42 cases of SAP patients with Enterococcus infection admitted in the hepatobiliary department of the Peoplels Hospital of Hunan Province from Sep 2005 to Dec 2008 was retrospective analyzed to observe the clinical and bacteriological efficacy, as well as the incidence of adverse reactions. RESULTS The clinical effective rate and the bacterial clearance rate of SAP patients with Enterococcus infection were 80.9% and 85.7%, respectively, after the teicoplanin administered and no significant adverse occurred caused by teicoplanin events. CONCLUSIONS Teicoplanin is safe, effective, economical and convenient in the treatment on SAP patients with Enterococcus infections and is worth to be recommended in clinic.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2010年第4期557-558,共2页
Chinese Journal of Nosocomiology
关键词
替考拉宁
肠球菌属
重症胰腺炎
回顾性研究
Teicoplanin
Enterococcus
Severe acute paneretitis
Retrospective study
